CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Background: Several drugs are available for the preventive treatment of both episodic and chronic migraine. The choice of which therapy to initiate first, second, or third is not straightforward and is based on multiple factors, including general efficacy, tolerability, potential for serious adverse events, comorbid conditions, and costs. Recently, a new class of migraine preventive drugs was introduced, i.e. monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor. Methods: The present article summarizes the evidence gathered with this new migraine preventive drug class from randomized placebo-controlled clinical trials. It further puts this into perspective next to the evidence gained by the most widely used agents for the prevention of episodic and chronic migraine with an emphasis on efficacy and the robustness with which this efficacy signal was obtained. Results: Although being a relatively new class of migraine preventive drugs, monoclonal antibodies blocking the CGRP pathway have an efficacy which is at least comparable if not higher than those of the currently used preventive drugs. Moreover, the robustness of this efficacy signal is substantiated by several randomized clinical trials each including large numbers of patients. In addition, because of their excellent tolerability and with long-term safety data emerging, they seem to have an unprecedented efficacy over adverse effect profile, clearly resulting in an added value for migraine prevention. Conclusions: Balancing the data presented in the current manuscript with additional data concerning long term safety on the one hand and cost issues on the other hand, can be of particular use to health policy makers to implement this new drug class in the prevention of migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although many well-evidenced medications exist, including newer targeted biologics, not all patients experience symptom relief, highlighting the need for additional treatment approaches.3”
From Acceptance-Commitment Therapy for Women with Episodic Migraine: A Pilot Randomized Trial (2024) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994
Diener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960
A Controlled Trial of Erenumab for Episodic Migraine
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1705848 · Cited by 928
Self-citationSilberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Fremanezumab for the Preventive Treatment of Chronic Migraine
Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709038 · Cited by 792
Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Doležil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30083-2 · Cited by 722
Self-citation
Research works printed but not linked: 2
- Mulleners WM, Haan J, Dekker F, Jko T, Wbo H, Tqfdjgjfl B et al (2010) Preventieve behandeling van migraine. Ned Tijdschr Geneeskd 154:1–9
- Solomon GDSA (1986) Verapamil and propranolol in migraine prophylaxis: a double-blind, cross over study. Headache. 26:325
Cited by
Sacco, S., Amin, F. M., Ashina, M., Bendtsen, L., Deligianni, C. I., Gil-Gouveia, R., Katsarava, Z., MaassenVanDenBrink, A., Martelletti, P., Mitsikostas, D.-D., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01431-x · Cited by 410
“Among the oral prophylactics, high dropout rates were reported especially for amitriptyline, valproate or topiramate [37].”
BackgroundSelf-citationYang, D., Jacobson, A., Meerschaert, K. A., Sifakis, J. J., Wu, M., Chen, X., Yang, T., Zhou, Y., Anekal, P. V., Rucker, R. A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.024 · Cited by 224
Lampl, C., MaassenVanDenBrink, A., Amin, F. M., Deligianni, C. I., Gil-Gouveia, R., Jassal, T., Sanchez-Del-Rio, M., Reuter, U., Uluduz, D., Versijpt, J., et al. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01594-1 · Cited by 182
Self-citationBarbanti, P., Egeo, G., Aurilia, C., Altamura, C., d’Onofrio, F., Finocchi, C., Albanese, M., Aguggia, M., Rao, R., Zucco, M., et al. (2022) · The Journal of Headache and Pain · doi:10.1186/s10194-022-01498-6 · Cited by 111
“Their distinguishing feature is the considerable proportions of responders (≥ 50% reduction in monthly migraine days) and super-responders (≥ 75% reduction in monthly migraine days), and the excellent efficacy and tolerability ratio which represents a substantial step forward compared to the usual standard of care [3,…”
BackgroundCalcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Versijpt, J. J., Paemeleire, K., Reuter, U., & MaassenVanDenBrink, A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00109-6 · Cited by 94
Self-citation
Metadata
- Authors
- Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J.
- Affiliations
- Vrije Universiteit Brussel (BE)
- Ghent University Hospital (BE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University of Liège (BE)
- Corresponding author
- Versijpt, Jan
- Venue
- The Journal of Headache and Pain
- Published
- 2021-10-25
- Volume
- 22
- Issue
- 1
- Pages
- 128-128
- ISSN
- 1129-2369 (ISSN-L)
- 1129-2377
- PMC
- PMC8547103
- OpenAlex
- W3208701883
- Cited by
- 121
- References
- 94
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 36 · 2022: 34 · 2021: 1
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- The Journal of Headache and Pain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
- Keywords
- migraine prophylaxis, CGRP monoclonal antibodies, calcitonin gene-related peptide, CGRP receptor antagonists, episodic migraine, chronic migraine, drug efficacy, tolerability, adverse events, long-term safety, cost-effectiveness, health policy
- MeSH terms
- Antibodies, Monoclonal, Calcitonin, Pharmaceutical Preparations, Humans, Migraine Disorders, Calcitonin Gene-Related Peptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. https://app.cochat.ai/papers/10.1186/s10194-021-01335-2
- The paper
- Vandervorst, F., Van Deun, L., Van Dycke, A., Paemeleire, K., Reuter, U., Schoenen, J., & Versijpt, J. (2021). CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. The Journal of Headache and Pain. https://doi.org/10.1186/s10194-021-01335-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.